טוען...
Cell cycle and beyond: Exploiting new RB1 controlled mechanisms for cancer therapy
Recent studies highlight the importance of the RB1 tumor suppressor as a target for cancer therapy. Canonically, RB1 regulates cell cycle progression and represents the down-stream target for CDK4/6 inhibitors that are in clinical use. However, newly discovered features of the RB1-pathway suggest ne...
שמור ב:
| הוצא לאור ב: | Trends Cancer |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6719339/ https://ncbi.nlm.nih.gov/pubmed/31174843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trecan.2019.03.005 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|